• Home
  • News
  • Market Data
  • Participants
  • Issuers
  • Investors
  • Education
  • Profile

Cookie notification

Our website uses cookies. This enables us to optimize your user experience. By continuing to use our website, you agree to this. To find out more, please see our Privacy Policy.


Europe's leading exchange for Life Sciences

SIX Swiss Exchange offers Swiss and foreign Life Sciences companies ideal conditions for raising capital. As a proactive partner, SIX Swiss Exchange facilitates an efficient listing and access to financially powerful Swiss and international investors and high liquidity.

Switzerland has the world's highest per capita density of bio and medtech companies. This is the result of a long-standing and fruitful interactive relationship between the well-established Swiss pharma, biotech and medtech industries and the country's financial institutions.

The centre for Life Sciences companies in Europe

SIX Swiss Exchange is Europe's leading exchange for Life Sciences companies, representing more than one third of the European Life Sciences market capitalization across Europe's major stock exchanges. Switzerland's capital-rich investor base, strong banking system and its leading industry know-how make up the country's vibrant Life Sciences ecosystem. This enables companies to efficiently raise capital with the view to drive scientific discovery through to market launch.

The most prominent stock markets in the Life Sciences sector in Europe*

Sources: SIX and STOXX, January 2020
*by total market capitalization in EUR bn

The leading European exchange for Life Sciences IPOs

In 2000, Actelion was listed on the Swiss Stock Exchange, and over time it became the largest European pure-play listed biotech firm. The successful Actelion story ended with a USD 30 billion takeover bid by Johnson & Johnson in 2017. But the next chapter opened with Idorsia – an R&D company which was spun off as a contribution in-kind to the former shareholders of Actelion. Idorsia listed on the Swiss Stock exchange in June 2017 with a market capitalization of about CHF 1.5 billion as of the closing on the first trading day. In 2019, Alcon joined the Swiss Stock Exchange as the largest spin-off to date in Switzerland. It is a great example of a successful primary double listing on SIX and a foreign exchange (NYSE). SIX is also attractive for cross-border listings, as the examples of Newron, Cosmo, IGEA Pharma or Cassiopea have shown in recent years. In addition, the most prominent global pharmaceutical players, Novartis and Roche, feature among the issuer base of the Swiss Stock Exchange and lay the foundations for a well-diversified peer group whose strong appeal reaches far beyond Switzerland’s borders.

High profile among investors, analysts and media

Life Sciences companies listed on the Swiss Stock exchange benefit from outstanding visibility among investors and the media, as well as broad coverage by analysts specializing in this sector. Extensive sector-specific expertise enables companies to expect a stable market environment and an attractive valuation.

Find out more about the advantages of Switzerland as a Life Sciences hub and the added value of a listing on SIX Swiss Exchange in our factsheet[pdf].